

**Wright Medical Group, Inc.**  
**Reconciliation of Net Sales to Net Sales Excluding the Impact of Foreign Currency**  
(dollars in thousands--unaudited)

	Three Months Ended December 31, 2010		Twelve Months Ended December 31, 2010	
	International Net Sales	Total Net Sales	International Net Sales	Total Net Sales
<b>Net sales, as reported</b>	\$ 57,107	\$ 138,287	\$ 208,990	\$ 518,973
Currency impact as compared to prior period	344	344	(1,496)	(1,496)
<b>Net sales, excluding the impact of foreign currency</b>	<u>\$ 57,451</u>	<u>\$ 138,631</u>	<u>\$ 207,494</u>	<u>\$ 517,477</u>

**Wright Medical Group, Inc.**  
**Reconciliation of As Reported Results to Non-GAAP Financial Measures**  
(in thousands, except per share data--unaudited)

	Three Months Ended		Twelve Months Ended	
	December 31, 2010	December 31, 2009	December 31, 2010	December 31, 2009
<b>Operating Income</b>				
<b>Operating income, as reported</b>	\$ 15,169	\$ 4,500	\$ 37,174	\$ 23,951
<i>Reconciling items impacting Gross Profit:</i>				
Inventory step-up amortization	-	-	-	70
Non-cash, stock-based compensation	321	347	1,301	1,285
Total	321	347	1,301	1,355
<i>Reconciling items impacting Selling, General and Administrative expenses:</i>				
Non-cash, stock-based compensation	2,224	2,255	9,924	10,077
U.S. governmental inquiries/DPA related	1,283	186	10,902	7,845
Write-down of international receivable	-	5,579	-	5,579
Total	3,507	8,020	20,826	23,501
<i>Reconciling items impacting Research and Development expenses:</i>				
Non-cash, stock-based compensation	452	389	1,952	1,829
<i>Other Reconciling Items:</i>				
Restructuring charges	(220)	2,553	919	3,544
<b>Operating income, as adjusted</b>	<u>\$ 19,229</u>	<u>\$ 15,809</u>	<u>\$ 62,172</u>	<u>\$ 54,180</u>
<b>Operating income, as adjusted, as a percentage of net sales</b>	<u>13.9%</u>	<u>12.2%</u>	<u>12.0%</u>	<u>11.1%</u>

**Wright Medical Group, Inc.**  
**Reconciliation of As Reported Results to Non-GAAP Financial Measures (continued)**  
(in thousands, except per share data--unaudited)

	<u>Three Months Ended</u>		<u>Twelve Months Ended</u>	
	<u>December 31,</u> <u>2010</u>	<u>December 31,</u> <u>2009</u>	<u>December 31,</u> <u>2010</u>	<u>December 31,</u> <u>2009</u>
<b>Net Income</b>				
<b>Income before taxes, as reported</b>	\$ 13,736	\$ (223)	\$ 30,921	\$ 15,612
<i>Pre-tax impact of reconciling items:</i>				
Non-cash, stock-based compensation	2,997	2,991	13,177	13,191
Restructuring charges	(220)	2,553	919	3,544
Inventory step-up amortization	-	-	-	70
U.S. governmental inquiries/DPA related	1,283	186	10,902	7,845
Write-down of international receivable	-	5,579	-	5,579
CTA write-off	-	2,643	-	2,643
<b>Income before taxes, as adjusted</b>	<u>17,796</u>	<u>13,729</u>	<u>55,919</u>	<u>48,484</u>
<b>Provision for income taxes, as reported</b>	4,867	(2,458)	13,080	3,481
Non-cash, stock-based compensation	1,144	896	4,410	3,901
Restructuring charges	(67)	2,882	376	3,269
Inventory step-up amortization	-	-	-	27
U.S. governmental inquiries/DPA related	81	(208)	2,266	2,789
Write-down of international receivable	-	1,817	-	1,817
<b>Provision for income taxes, as adjusted</b>	<u>6,025</u>	<u>2,929</u>	<u>20,132</u>	<u>15,284</u>
<b>Effective tax rate, as adjusted</b>	<u>33.9%</u>	<u>21.3%</u>	<u>36.0%</u>	<u>31.5%</u>
<b>Net income, as adjusted</b>	<u>\$ 11,771</u>	<u>\$ 10,800</u>	<u>\$ 35,787</u>	<u>\$ 33,200</u>

	<u>Three Months Ended</u>		<u>Three Months Ended</u>	
	<u>December 31, 2010</u>		<u>December 31, 2009</u>	
	<u>As Reported</u>	<u>As Adjusted</u>	<u>As Reported</u>	<u>As Adjusted</u>
<b>Basic net income</b>	\$ 8,869	\$ 11,771	\$ 2,235	\$ 10,800
Interest expense on convertible notes	935	935	N/A	935
<b>Diluted net income</b>	\$ 9,804	\$ 12,706	\$ 2,235	\$ 11,735
<b>Basic shares</b>	37,962	37,962	37,470	37,470
Dilutive effect of stock options and restricted shares	147	147	248	248
Dilutive effect of convertible notes	6,126	6,126	N/A	6,126
<b>Diluted shares</b>	44,235	44,235	37,718	43,844
<b>Net income per share, diluted</b>	<u>\$ 0.22</u>	<u>\$ 0.29</u>	<u>\$ 0.06</u>	<u>\$ 0.27</u>

**Wright Medical Group, Inc.**  
**Reconciliation of As Reported Results to Non-GAAP Financial Measures (continued)**  
(in thousands, except per share data--unaudited)

	<b>Twelve Months Ended</b>		<b>Twelve Months Ended</b>	
	<b>December 31, 2010</b>		<b>December 31, 2009</b>	
	<u>As Reported</u>	<u>As Adjusted</u>	<u>As Reported</u>	<u>As Adjusted</u>
<b>Basic net income</b>	\$ 17,841	\$ 35,787	\$ 12,131	\$ 33,200
Interest expense on convertible notes	N/A	3,740	N/A	3,740
<b>Diluted net income</b>	\$ 17,841	\$ 39,527	\$ 12,131	\$ 36,940
<b>Basic shares</b>	37,802	37,802	37,366	37,366
Dilutive effect of stock options and restricted shares	159	159	77	77
Dilutive effect of convertible notes	N/A	6,126	N/A	6,126
<b>Diluted shares</b>	37,961	44,087	37,443	43,569
<b>Net income per share, diluted</b>	<u>\$ 0.47</u>	<u>\$ 0.90</u>	<u>\$ 0.32</u>	<u>\$ 0.85</u>

	<b>Three Months Ended</b>		<b>Twelve Months Ended</b>	
	<b>December 31,</b>	<b>December 31,</b>	<b>December 31,</b>	<b>December 31,</b>
	<b>2010</b>	<b>2009</b>	<b>2010</b>	<b>2009</b>
<b>Net Income per Diluted Share</b>				
<b>Net income, as reported, per diluted share</b>	\$ 0.22	\$ 0.06	\$ 0.47	\$ 0.32
Interest expense on convertible notes	N/A	0.02	0.08	0.09
Dilutive effect of convertible notes	N/A	(0.01)	(0.07)	(0.05)
Non-cash, stock-based compensation	0.04	0.05	0.20	0.21
Restructuring charges	0.00	(0.01)	0.01	0.01
Inventory step-up amortization	-	-	-	0.00
U.S. governmental inquiries/DPA related	0.03	0.01	0.20	0.12
Write-down of international receivable	-	0.09	-	0.09
CTA write-off	-	0.06	-	0.06
<b>Net income, as adjusted, per diluted share</b>	<u>\$ 0.29</u>	<u>\$ 0.27</u>	<u>\$ 0.90</u>	<u>\$ 0.85</u>